-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
January 23, 2022/eMedClub News/--Recently, CytomX Therapeutics announced that the U.
S.
Food and Drug Administration (FDA) has approved the company’s investigational new drug, T cell-directing bispecific antibody CX-904 ( IND) application, aiming to selectively bind EGFR receptors on cancer cells and CD3 receptors on T cells in the tumor microenvironment to direct cytotoxic T cells to attack cancer cells
.
As early as 2017, Amgen reached a strategic cooperation agreement with CytomX Therapeutics to jointly develop Probody, a T-cell-directed dual-antibody platform, for the treatment of cancer cells
.
If all goes well with drug development on the platform, including CX-904, CytomX is expected to receive up to $1.
5 billion in funding
.
CX-904 is a conditionally activated T-cell bispecific antibody that binds T-cell bispecific antibodies.
It has great potential for the treatment of solid tumors by directing T-cells against epidermal growth factor receptor (EGFR) tumor antigens
.
CX-904 will also bind a peptide to reduce binding to healthy tissue and prevent side effects
.
That means it can target tumor-associated antigens that are present in healthy cells
.
▲ Schematic diagram of the Probody platform (Image source: CytomX official website) "The impressive innovation of the CX-904 design and its advancement in the clinical setting underscores our commitment to destroy cancer in different ways
.
The IND for CX-904 also marks the sixth therapeutic candidate and third treatment modality to enter the clinic from our versatile and tunable Probody platform, strengthening our leadership in conditional activation biotherapeutics," said CytomX Sean McCarthy, Chief Executive Officer and Chairman, said, "We are eager to initiate a Phase 1 dose-escalation study of CX-904 as the frontier of our broad efforts to bring conditionally activated bispecifics to patients with advanced solid tumors
.
"T-cell bispecific antibodies T-cell bispecific antibodies (TEB) are a new class of cancer immunotherapy drugs that can significantly improve clinical efficacy and safety compared to traditional immunotherapy
.
T-cell bispecific antibodies simultaneously bind tumor cells Surface antigens bind to T-cell CD3 receptors, activate the latter and physically cross-link them to target cells, thereby exerting antitumor activity
.
This integrative immunization approach is particularly beneficial against tumors that are less immunogenic and lack neoantigens, Because T cells can be recruited and activated independently of their receptor specificity , this stringent tumor-targeted immunomodulation is also expected to reduce systemic inflammatory toxicity compared to traditional immunotherapy .
▲ T cell bispecific antibody design Principle (Image source: CytomX official website) As one of the most powerful anti-cancer effect mechanisms, TEB has achieved very promising early clinical data in some hematological tumors (such as REGN1979 and Roche's CD20-TCB), and it is expected to be in It will be approved by the FDA in the near future .
Recommended reading: The CD3/CD20 double antibody purchased by Zai Lab has been approved for clinical use, and the double/multi-specific antibody drug has become a research and development trendYimai Meng broke the news of Roche CD3/CD20 Double antibodies are planned to be included in breakthrough therapy varietiesYimai Meng revealed that the development of TEB in solid tumors is slightly slower, mainly because of the difficulty in target selection and the high toxicity in normal tissues .
The targets of solid tumors can be classified as only expressed in tumors targets and targets that are less expressed in normal tissues.
Very ideal targets like the former have not been found so far, for example: CLDN6
.
Many drugs under development use the latter target, and many corresponding countermeasures have begun to be studied in depth, especially in non-inflammatory or low-inflammatory solid tumors that are currently incapable of immunotherapy, TEB is expected to make historic changes.
.
Since it is expressed in normal tissues, how to improve the therapeutic index (therapeutic index) becomes the key
.
The research methods include 2+1 molecular format (such as Genentech's HER2xCD3), tumor microenvironment-activating antibodies (such as Cytomx's Probody, Maverick's COBRA platform), fractionated priming dosing,
etc.
These new solutions or means to deal with solid tumors are currently setting off a wave in the field of dual antibodies.
Taking CytomX as an example, Amgen is not the first biopharmaceutical giant interested in CytomX's Probody therapy.
In December 2021, AI BoVie has reached a $500 million deal with CytomX for a CD71-targeted drug candidate and two undisclosed drug candidates, and this conditionally activated antibody-drug conjugate (ADC) has entered Phase 2 clinical trials
.
Recommended reading: Targeting CD71, the latest clinical data of ADC drugs jointly developed by AbbVie announcedYimai Meng broke the newsIn March 2020, Japanese pharmaceutical companies Astellas Pharma and CytomX established a company worth more than 1.
6 billion US dollars A strategic partnership to discover and develop novel T-cell engaging bispecific antibodies targeting CD3 and tumor cell surface antigens to treat cancer
.
Recommended reading: Bet on CD3/Tumor Cell Surface Antigen Bispecific Antibody! Japanese pharmaceutical company Astellas and CytomX have reached a strategic cooperation of over US$1.
6 billionMedical Mai Hei Technology and earlier, Bristol-Myers (BMS) Expanded a collaboration with CytomX in 2014 to receive eight additional targeted drug candidates for an upfront payment of $200 million
.
Reference: 1.
https:// -of-advanced-solid-tumors-/
S.
Food and Drug Administration (FDA) has approved the company’s investigational new drug, T cell-directing bispecific antibody CX-904 ( IND) application, aiming to selectively bind EGFR receptors on cancer cells and CD3 receptors on T cells in the tumor microenvironment to direct cytotoxic T cells to attack cancer cells
.
As early as 2017, Amgen reached a strategic cooperation agreement with CytomX Therapeutics to jointly develop Probody, a T-cell-directed dual-antibody platform, for the treatment of cancer cells
.
If all goes well with drug development on the platform, including CX-904, CytomX is expected to receive up to $1.
5 billion in funding
.
CX-904 is a conditionally activated T-cell bispecific antibody that binds T-cell bispecific antibodies.
It has great potential for the treatment of solid tumors by directing T-cells against epidermal growth factor receptor (EGFR) tumor antigens
.
CX-904 will also bind a peptide to reduce binding to healthy tissue and prevent side effects
.
That means it can target tumor-associated antigens that are present in healthy cells
.
▲ Schematic diagram of the Probody platform (Image source: CytomX official website) "The impressive innovation of the CX-904 design and its advancement in the clinical setting underscores our commitment to destroy cancer in different ways
.
The IND for CX-904 also marks the sixth therapeutic candidate and third treatment modality to enter the clinic from our versatile and tunable Probody platform, strengthening our leadership in conditional activation biotherapeutics," said CytomX Sean McCarthy, Chief Executive Officer and Chairman, said, "We are eager to initiate a Phase 1 dose-escalation study of CX-904 as the frontier of our broad efforts to bring conditionally activated bispecifics to patients with advanced solid tumors
.
"T-cell bispecific antibodies T-cell bispecific antibodies (TEB) are a new class of cancer immunotherapy drugs that can significantly improve clinical efficacy and safety compared to traditional immunotherapy
.
T-cell bispecific antibodies simultaneously bind tumor cells Surface antigens bind to T-cell CD3 receptors, activate the latter and physically cross-link them to target cells, thereby exerting antitumor activity
.
This integrative immunization approach is particularly beneficial against tumors that are less immunogenic and lack neoantigens, Because T cells can be recruited and activated independently of their receptor specificity , this stringent tumor-targeted immunomodulation is also expected to reduce systemic inflammatory toxicity compared to traditional immunotherapy .
▲ T cell bispecific antibody design Principle (Image source: CytomX official website) As one of the most powerful anti-cancer effect mechanisms, TEB has achieved very promising early clinical data in some hematological tumors (such as REGN1979 and Roche's CD20-TCB), and it is expected to be in It will be approved by the FDA in the near future .
Recommended reading: The CD3/CD20 double antibody purchased by Zai Lab has been approved for clinical use, and the double/multi-specific antibody drug has become a research and development trendYimai Meng broke the news of Roche CD3/CD20 Double antibodies are planned to be included in breakthrough therapy varietiesYimai Meng revealed that the development of TEB in solid tumors is slightly slower, mainly because of the difficulty in target selection and the high toxicity in normal tissues .
The targets of solid tumors can be classified as only expressed in tumors targets and targets that are less expressed in normal tissues.
Very ideal targets like the former have not been found so far, for example: CLDN6
.
Many drugs under development use the latter target, and many corresponding countermeasures have begun to be studied in depth, especially in non-inflammatory or low-inflammatory solid tumors that are currently incapable of immunotherapy, TEB is expected to make historic changes.
.
Since it is expressed in normal tissues, how to improve the therapeutic index (therapeutic index) becomes the key
.
The research methods include 2+1 molecular format (such as Genentech's HER2xCD3), tumor microenvironment-activating antibodies (such as Cytomx's Probody, Maverick's COBRA platform), fractionated priming dosing,
etc.
These new solutions or means to deal with solid tumors are currently setting off a wave in the field of dual antibodies.
Taking CytomX as an example, Amgen is not the first biopharmaceutical giant interested in CytomX's Probody therapy.
In December 2021, AI BoVie has reached a $500 million deal with CytomX for a CD71-targeted drug candidate and two undisclosed drug candidates, and this conditionally activated antibody-drug conjugate (ADC) has entered Phase 2 clinical trials
.
Recommended reading: Targeting CD71, the latest clinical data of ADC drugs jointly developed by AbbVie announcedYimai Meng broke the newsIn March 2020, Japanese pharmaceutical companies Astellas Pharma and CytomX established a company worth more than 1.
6 billion US dollars A strategic partnership to discover and develop novel T-cell engaging bispecific antibodies targeting CD3 and tumor cell surface antigens to treat cancer
.
Recommended reading: Bet on CD3/Tumor Cell Surface Antigen Bispecific Antibody! Japanese pharmaceutical company Astellas and CytomX have reached a strategic cooperation of over US$1.
6 billionMedical Mai Hei Technology and earlier, Bristol-Myers (BMS) Expanded a collaboration with CytomX in 2014 to receive eight additional targeted drug candidates for an upfront payment of $200 million
.
Reference: 1.
https:// -of-advanced-solid-tumors-/
